175 related articles for article (PubMed ID: 27279321)
1. Severe recalcitrant psoriasis treated with itolizumab, a novel anti-CD6 monoclonal antibody.
Gupta A; Sharma YK; Deo K; Kothari P
Indian J Dermatol Venereol Leprol; 2016; 82(4):459-61. PubMed ID: 27279321
[No Abstract] [Full Text] [Related]
2. Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.
Dogra S; Uprety S; Suresh SH
Expert Opin Biol Ther; 2017 Mar; 17(3):395-402. PubMed ID: 28064543
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
Krupashankar DS; Dogra S; Kura M; Saraswat A; Budamakuntla L; Sumathy TK; Shah R; Gopal MG; Narayana Rao T; Srinivas CR; Bhat R; Shetty N; Manmohan G; Sai Krishna K; Padmaja D; Pratap DV; Garg V; Gupta S; Pandey N; Khopkar U; Montero E; Ramakrishnan MS; Nair P; Ganapathi PC
J Am Acad Dermatol; 2014 Sep; 71(3):484-92. PubMed ID: 24703722
[TBL] [Abstract][Full Text] [Related]
4. Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.
Aira LE; López-Requena A; Fuentes D; Sánchez L; Pérez T; Urquiza A; Bautista H; Falcón L; Hernández P; Mazorra Z
MAbs; 2014; 6(3):783-93. PubMed ID: 24594862
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab.
Hernández P; Moreno E; Aira LE; Rodríguez PC
Curr Drug Targets; 2016; 17(6):666-77. PubMed ID: 26844560
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD6 mAbs for the treatment of psoriasis.
Dogra S; D S; Rajagopalan M
Expert Opin Biol Ther; 2020 Oct; 20(10):1215-1222. PubMed ID: 32466689
[TBL] [Abstract][Full Text] [Related]
7. Itolizumab provides sustained remission in plaque psoriasis: a 5-year follow-up experience.
Budamakuntla L; Madaiah M; Sarvajnamurthy S; Kapanigowda S
Clin Exp Dermatol; 2015 Mar; 40(2):152-5. PubMed ID: 25495868
[TBL] [Abstract][Full Text] [Related]
8. Long-term therapy with itolizumab is safe and effective for patients with moderate to severe psoriasis: Results from an expanded-access program.
Falcón Lincheta L; Saumell Nápoles Y; Gray Lovio OR; Viqueira Fuentesfría AM; Pérez Alonso T; Batista Romagoza M; Urquiza Rodríguez A; Mantecón Fernández B; Bautista Jerez HA; Fernández de Armas D; Martínez Matute ES; León García Y; Oramas Fernández DK; Marrero Chavez Y; Fernandez Lorente A; Valls Hung AR; Lorenzo-Luaces P; Valenzuela Silva C; Moreno E; Hernández-Casaña P
Int Immunopharmacol; 2024 Jun; 134():112225. PubMed ID: 38759368
[TBL] [Abstract][Full Text] [Related]
9. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.
Filgueira LM; Cervantes JB; Lovelle OA; Herrera C; Figueredo C; Caballero JA; Sánchez N; Berrio J; Lorenzo G; Cepeda M; Ramos M; Saavedra D; Añe-Kouri AL; Mazorra Z; Leon K; Crombet T; Caballero A
Immunotherapy; 2021 Mar; 13(4):289-295. PubMed ID: 33397150
[TBL] [Abstract][Full Text] [Related]
10. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.
Bughani U; Saha A; Kuriakose A; Nair R; Sadashivarao RB; Venkataraman R; Patel S; Deshchougule AT; S SK; Montero E; Pai HV; Palanivelu DV; Melarkode R; Nair P
PLoS One; 2017; 12(7):e0180088. PubMed ID: 28672038
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study.
Dogra S; D S K; Budamakuntla L; Srinivas CR; Khopkar U; Gupta S; Shetty N; Pratap DV; Gopal MG; Rao TN; Garg V; Sumathy TK; Saraswat A; Bhat R; Kura M; Pandey N; Shah R; Sai Krishna K; Padmaja D; Manmohan G; M S R; Barve A; Montero E
J Am Acad Dermatol; 2015 Aug; 73(2):331-3.e1. PubMed ID: 26183983
[No Abstract] [Full Text] [Related]
12. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
[TBL] [Abstract][Full Text] [Related]
13. Dermatomyositis associated with anti-tumor necrosis factor therapy in a patient with psoriasis.
Dicaro D; Bowen C; Dalton SR
J Am Acad Dermatol; 2014 Mar; 70(3):e64-5. PubMed ID: 24528921
[No Abstract] [Full Text] [Related]
14. Resident Rounds. Part III A. Serendipitous improvement in moderate to severe acne in psoriasis patients treated with ustekinumab: a two-case series.
Jensen JD; Huynh T; Cafardi J; Sami N
J Drugs Dermatol; 2013 Jun; 12(6):710-1. PubMed ID: 23839194
[No Abstract] [Full Text] [Related]
15. Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients.
Vitiello M; Tosti A; Abuchar A; Zaiac M; Kerdel FA
Int J Dermatol; 2013 Mar; 52(3):358-62. PubMed ID: 23330782
[No Abstract] [Full Text] [Related]
16. Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis.
Menon R; David BG
Clin Cosmet Investig Dermatol; 2015; 8():215-22. PubMed ID: 25945063
[TBL] [Abstract][Full Text] [Related]
17. Recalcitrant pustular psoriasis successfully treated with adalimumab.
Alvarez AC; Rodríguez-Nevado I; De Argila D; Rubio FP; Rovira I; Torrelo A; Zambrano A
Pediatr Dermatol; 2011; 28(2):195-7. PubMed ID: 21504452
[TBL] [Abstract][Full Text] [Related]
18. Clinical and experimental evidence for targeting CD6 in immune-based disorders.
Consuegra-Fernández M; Lin F; Fox DA; Lozano F
Autoimmun Rev; 2018 May; 17(5):493-503. PubMed ID: 29526637
[TBL] [Abstract][Full Text] [Related]
19. A case of psoriasis verrucosa successfully treated with adalimumab.
Maejima H; Katayama C; Watarai A; Nishiyama H; Katsuoka K
J Drugs Dermatol; 2012 Nov; 11(11):e74-5. PubMed ID: 23135098
[TBL] [Abstract][Full Text] [Related]
20. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
Leonardi C; Matheson R; Zachariae C; Cameron G; Li L; Edson-Heredia E; Braun D; Banerjee S
N Engl J Med; 2012 Mar; 366(13):1190-9. PubMed ID: 22455413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
